The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Subscribe To Our Newsletter & Stay Updated
